Inclusion Criteria:  Written informed consent obtained. Age ≥ 18 years at the time of study entry. Histological or Cytologically diagnosed gynecological malignancies. Failure to prior standard treatment (surgery, chemotherapy, radiotherapy); Refractory/recurrence/metastasis gynecological cancer At least one measurable lesion according to the RECIST1.1. Cooperative Oncology Group-Status (ECOG Status) 0-3. The last treatment should be over 2 weeks.  Exclusion Criteria:  History or evidence of active autoimmune disease that requires systemic treatment. Participated in other anti-tumor clinical trials within 4 weeks. Patients who have a contraindication to similar drugs. That failure to follow up regularly.